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Abstract
Tracking the dynamic motion of individual nanoparticles or viruses offers quantitative insights 
into their real-time behavior and fate in different biological environments. Indeed, particle 
tracking is a powerful tool that has facilitated the development of drug carriers with enhanced 
penetration of mucus, brain tissues and other extracellular matrices. Nevertheless, heterogeneity is 
a hallmark of nanoparticle diffusion in such complex environments: identical particles can exhibit 
strongly hindered or unobstructed diffusion within microns of each other. The common practice in 
2D particle tracking, namely analyzing all trackable particle traces with equal weighting, naturally 
biases toward rapidly diffusing sub-populations at shorter time scales. This in turn results in 
misrepresentation of particle behavior and a systematic underestimate of the time necessary for a 
population of nanoparticles to diffuse specific distances. We show here via both computational 
simulation and experimental data that this bias can be rigorously corrected by weighing the 
contribution by each particle trace on a ‘frame-by-frame’ basis. We believe this methodology 
presents an important step towards objective and accurate assessment of the heterogeneous 
transport behavior of submicron drug carriers and pathogens in biological environments.
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Analysis of the real-time motion of biological and synthetic particles, commonly referred to 
as single- or multiple-particle tracking (MPT) [1-3], is an increasingly popular approach to 
gaining insight into dynamic processes in living systems, such as the diffusion of proteins 
and lipids in cell membranes [4, 5], the kinetics and intracellular processes involved in viral 
infections [6, 7] as well as the mobility of pathogens in biofilms or mucus [8-10]. Because 
the motions of particles in an environment are governed by local viscous and elastic forces, 
particle traces from MPT can be further analyzed to infer the microstructural, rheological 
and barrier properties of different materials at the length scales relevant to nanoparticles and 
viral pathogens [11-14]. Particle tracking has been used extensively in the field of drug 
delivery, not only to characterize important barriers to drug delivery but also to quantify the 
extent to which engineered drug carriers can overcome these barriers. Indeed, MPT has 
enabled the development of nanoparticles capable of penetrating various mucus secretions 
[15-18], brain tissues [19] and other physiological gels [20-22], as well as investigations into 
the intracellular trafficking of nonviral gene carriers and polymeric nanoparticles [23-26].
Nevertheless, biological environments tend to be highly complex, often composed of a 
dense matrix of proteins, carbohydrates, cells and other biomacromolecules, and exhibiting a 
broad range of pore sizes. Particles introduced into such biological fluids will inevitably 
encounter varying degrees of steric obstruction and/or molecular interactions with the 
network. As particle sizes approach the characteristic mesh spacing of the network elements, 
the particles may exhibit increasingly heterogeneous motions, leading to orders of 
magnitude differences in mean squared displacements (MSD) and effective diffusivities 
(Deff) within the same particle population. In addition, the same particles may also exhibit 
distinct affinity to network elements; for example, otherwise identical viruses with different 
numbers of surface-bound antibodies may possess different antibody-mucin avidity [9, 27], 
and variations in the surface properties within a population of synthetic nanoparticles may 
likewise result in heterogeneous interactions with the matrix constituents. Thus, accurate 
measurement of the true distribution of particle behavior is essential to correctly assess the 
transport kinetics of nano drug carriers and other nanoparticulates.
While an intrinsic advantage of particle tracking is that it offers a means of capturing 
heterogeneity across individual particle traces, particle tracking data can suffer from 
inherent biases. The conventional practice in particle tracking is to obtain video recordings 
of particles in a medium, track their movements to quantify 2D particle displacements over 
time, and finally compute ensemble averages and distributions across all traces. Numerous 
particle detection and tracking methods exist [28-30], but a common and critical technical 
challenge emerges when particle tracking is applied to sub-micron entities capable of rapid 
diffusion into and out of the plane of focus (or scanning volume for 3D imaging). Such rapid 
diffusion results in shorter traces recorded for the majority of faster particles, and longer 
traces recorded for slower particles. When particles exhibit heterogeneous behavior, the 
calculated ensemble MSD and Deff at longer time scales inherently biases toward the slower 
subpopulation, since most fast-moving particle traces are too short to contribute MSD and 
Deff values at these time scales. This fundamental limitation, discussed previously [31, 32], 
can only be lessened by longer tracking times or improved depth of tracking.
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A less recognized and opposite bias occurs at shorter time scales, where relative 
contributions to the ensemble or distribution of MSD and Deff skew towards faster particles. 
This bias naturally arises because (1) the same fast-moving particle may appear multiple 
times in the focal plane as distinct traces, and (2) distinct particles may enter and leave the 
focal plane throughout the movie, and the rate at which these processes occur increases with 
particle speed. This bias is conceptually illustrated in Fig. 1, which shows that particle 
tracking in a fluid containing an equal mixture of fast- and slow-moving particles would 
result in a much greater number of fast-moving vs. slow-moving particle traces using 
standard 2D particle tracking analysis. Overestimating the fast-moving fraction represents a 
potential major concern when assessing the performance of drug carriers, since for many 
applications efficacy is correlated to the fraction of the drug carriers that can penetrate a 
biological barrier. Here, we present a simple and rigorous algorithm to correct for this bias 
with 2D particle tracking data, without requiring 3D video microscopy.
2. Materials and Methods
2.1. Simulation of heterogeneous nanoparticle transport
We simulated 3D Brownian diffusion of a population of particles seeded at equal density in 
a defined volume with a bimodal distribution of effective diffusivity (Deff), one centered at 
0.001 μm2/s (corresponding to ‘strongly hindered’ particles) and another at 1 μm2/s 
(corresponding to ‘mobile’ particles) at a time scale of 0.0667 s (the time step of our 
simulation). These Deff values are comparable to those we previously measured for muco-
inert and muco-adhesive drug carrier nanoparticles in human mucus secretions [11, 16]. Deff 
values were used to calculate a step size, and the locations of the particles from point to 
point were simulated following Marsaglia's method [33]. Briefly, the coordinates of a 
particle were determined by randomly selecting values x1 and x2 from independent uniform 
distributions on (−1, 1) such that , and then calculating , 
, and , where d is the step size. Particle 
trajectories were ‘recorded’ if they were within a defined focal plane for a minimum of 5 
frames, and trajectory segments for the same particle separated by more than 5 frames were 
treated as distinct traces.
2.2. Preparation of nanoparticles and viruses
Fluorescent, carboxyl-modified polystyrene beads (PS-COOH) sized 100 and 200 nm were 
purchased from Molecular Probes (Eugene, OR). PEGylated nanoparticles (PS-PEG) were 
prepared by conjugating 2 kDa amine-modified PEG (Rapp Polymere, Tuebingen, 
Germany) to PS-COOH particles via a carboxyl-amine reaction, as published previously [16, 
34]. PS-COOH and PS-PEG solutions were adjusted to equal particle concentration based on 
fluorescence intensity and microscopy imaging. In acidic (pH ~4) human cervicovaginal 
mucus (CVM) samples, PS-COOH nanoparticles are muco-adhesive and nearly always 
uniformly strongly hindered, while PS-PEG nanoparticles are muco-inert and nearly always 
uniformly fast-moving. Thus, a 50:50 mixture of the two in human CVM would mimic a 
heterogeneous particle population containing both strongly hindered and mobile particles in 
mucus. Fluorescent HSV-1 virions were prepared via expression of a VP22-GFP tegument 
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protein construct, packaged at high copy numbers while maintaining native viral envelope 
integrity, as previously described [9]. Fluorescent, mCherry-Gag labeled HIV-1 virions 
pseudotyped with a YU-2 envelope were prepared similarly to previously described [8, 35].
2.3. Collection of human mucus
Human CVM was obtained from healthy female donors at random times in their menstrual 
cycles, following a protocol approved by the University of North Carolina Institutional 
Review Board (IRB), as previously described [16]. Briefly, undiluted CVM secretions, 
averaging 0.3 g per sample, were obtained from women using a self-sampling menstrual 
collection device; participants inserted the device into the vagina for at least 30 s, removed 
it, and placed it into a 50 mL centrifuge tube. Samples were centrifuged at 230 ×g for 2 min 
to collect the secretions. Samples used in this study had total anti-HSV-1 IgG <150 ng/mL, 
measured by whole virus ELISA as previously described [9]. Human airway mucus was 
obtained from healthy patients intubated for general anesthesia during elective surgery, 
following an IRB-approved protocol. After surgery, the endotracheal tube was removed 
from the patient, and mucus coating the tube was collected by centrifugation [36]. Airway 
mucus that was non-uniform in color or consistency or had visible blood contamination was 
discarded. Samples were stored at 4°C until microscopy, typically within 24 hours.
2.4. Multiple particle tracking in human mucus
Dilute particle solution (~108-109 particles/mL, 1 μL or 5% v/v) was mixed gently into 20 
μL of human mucus in custom-made chambers, and samples were incubated 1 hour at 37 °C 
before microscopy. The translational motions of the particles were recorded using an 
EMCCD camera (Evolve 512; Photometrics, Tucson, AZ) mounted on an inverted 
epifluorescence microscope (AxioObserver D1; Zeiss, Thornwood, NY), equipped with an 
Alpha Plan-Apo 100×/1.46 NA objective, environmental (temperature and CO2) control 
chamber and an LED light source (Lumencor Light Engine DAPI/GFP/543/623/690). 
Videos (512 × 512, 16-bit image depth) were captured with MetaMorph imaging software 
(Molecular Devices, Sunnyvale, CA) at a temporal resolution of 66.7 ms and spatial 
resolution of 10 nm (nominal pixel resolution 0.156 μm/pixel) for 20 s. The tracking 
resolution was determined by tracking the displacements of particles immobilized with a 
strong adhesive, following a previously described method [37]. Trajectories were analyzed 
using MATLAB software, following methods originally developed in IDL by Crocker and 
Hoffman [1]. Sub-pixel tracking resolution was obtained by determining the precise location 
of particle centroids by light intensity-weighted averaging of neighboring pixels. As with 
simulation data, trajectories less than 5 frames in length were excluded, and trajectories 
belonging to the same particle were treated as distinct traces if separated by more than 5 
frames.
2.5. Conventional vs. frame-by-frame MPT analysis
The coordinates of particle centroids for each individual trace were transformed into time-
averaged mean squared displacements (MSD or <Δr2(τ)>), calculated as <Δr2(τ)>= [x(t + τ) 
− x(t)]2 + [y(t + τ) − y(t)]2 (where displacements x and y are functions of time t and time 
scale or time lag τ), and Deff, calculated from MSD=4Deffτ, as previously demonstrated [8, 
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11, 16]. With conventional MPT analysis, ensemble averages and distributions of MSD or 
Deff were calculated based on all traces without any weighting. For frame-by-frame MPT 
analysis, calculations were first performed at the individual frame level based only on 
particles present in that particular frame (i.e., capturing instantaneous ‘snapshots’ of particle 
behavior), before averaging across all frames in the movie. For example, the geometrically-
averaged ensemble MSD was calculated by first averaging across the MSDs of particles 
present at each frame, and then averaging the resulting mean MSDs across all frames (Fig. 
S1). Trajectories of n ≥ 70 particles per frame and n ≥ 150 traces were analyzed for each 
experiment (see Table S1 for averages per dataset); note that the conventional minimum of 
100 individual particle traces throughout the video typically corresponds n ≤ 40 particles per 
frame. Trapped particles were defined by Deff < 10−1.5 μm2/s at τ = 0.2667 s (time scale 
corresponding to a minimum trajectory length of 5 frames and a frame rate of 15 Hz). This 
cutoff was determined empirically based on multiple datasets of strongly hindered and 
mobile nanoparticles (e.g., PS-COOH and PS-PEG nanoparticles) in human mucus [11, 16]; 
for particles 200 nm and larger, a Deff < 10−1.5 μm2/s effectively means that the particles 
move much less than their diameters within 0.2667 s.
2.6. First passage time analysis
In order to demonstrate how the choice of conventional vs. frame-by-frame weighting can 
impact predictions of particle population behavior, we performed a first passage time 
analysis and calculated the expected time for 10% and 50% of a particle population to pass 
through a 50 μm thick layer of mucus. Given the diffusivity D of a particle, the probability 
that the particle has not passed through a layer of thickness L as of a given time t may be 
described by an explicit “survival function”. Using T to denote the time it takes for the 
particle to pass through the layer, the formula for this “survival function” is
where exp is the exponential function and k is an integer from 0 to ∞. Suppose that a 
heterogeneous population of particles have individual diffusivities {Di} with respective 
weights {wi} where i ranges from 1 to the number of particles N. The expected fraction of 
particles that remain in the fluid layer as of time t is then equivalent to the following 
weighted survival function:
For the conventional weighting method, we set wi for all i. For the frame-by-frame method, 
wi is set to be the number of frames in which the ith particle is present. For each weighting, 
we calculated the times t10 and t50 for which P(T > t10) = 0.9 and P(T > t50) = 0.5.
Wang et al. Page 5














Data averages are presented as means with standard error of the mean (SEM), unless 
otherwise indicated. Statistical significance was determined by a one-tailed, Student's t-test 
(α = 0.05). For first passage time analysis, due to inherent variations in the first passage 
times for different data sets, statistical significance was determined for time estimates based 
on frame-by-frame analysis normalized to corresponding time estimates based on 
conventional analysis (a value of 1 indicates no difference).
3. Results
To measure the extent of the bias toward faster particles at shorter time scales and to 
evaluate methods to correct for it, we first obtained a ‘ground-truth’ dataset reflecting 
known particle heterogeneity in a complex environment by simulating 3D Brownian 
diffusion of a 50:50 mixture of randomly seeded ‘mobile’ and ‘strongly hindered’ particles 
(see Methods). Following conventional MPT analysis practice, we examined the Deff 
distribution based on all traces. At a time scale of 0.2667 s (corresponding to a minimum of 
5 frames per trace and a frame rate of 15 Hz), the Deff distribution was markedly skewed 
towards the fast-moving particles (~85% vs. the theoretical 50%; Fig. 2A). Only roughly 
25% of traces were accounted for by particles present in the focal plane at the start of the 
simulation, while the remaining 75% were ‘excess’ traces due to these particles leaving and 
re-entering the focal plane multiple times, or to new particles entering the focal plane (Fig. 
S2; also see Table S1). Not surprisingly, the geometrically-averaged ensemble MSD (Fig. 
2B) showed a similar bias toward the faster fraction at shorter time scales (~10-fold higher 
than expected at a time scale of 0.2667 s).
To validate this in silico prediction, we next performed MPT on an equal mixture of 
fluorescent 200 nm PEG-modified (PS-PEG; muco-inert and nearly uniformly fast-moving, 
see Fig. S3) and carboxyl-modified (PS-COOH; muco-adhesive and nearly uniformly 
strongly hindered) polystyrene beads introduced into human cervicovaginal mucus. Our 
results, in good agreement with the analysis of simulated data above, show that the Deff 
distribution (Fig. 2C) was skewed substantially toward faster-moving particle fractions 
(again ~85% vs. the theoretical 50%), and the geometrically-averaged ensemble MSD (Fig. 
2D) was ~5-fold greater at a time scale of 0.2667 s than the geometric average of the MSDs 
for PS-PEG and PS-COOH measured separately. Naturally, any subsequent analysis or 
derivation based on this dataset would overweigh contributions by the fast-moving 
subpopulations of PS-PEG particles, which would in turn result in artificial and significant 
overestimates of the true fraction of particles that can diffuse across a mucus layer of a given 
thickness over time.
To resolve this bias, we hypothesized that each instantaneous snapshot of an imaging 
volume approximately captures the distribution of particle behavior at that instant; in other 
words, the fraction of ‘mobile’ vs. ‘strongly hindered’ particles is approximately at steady 
state and thus time-independent over the time frame of analysis. Averaging across a series of 
snapshots over the duration of a recorded movie would in turn provide an accurate measure 
of the true heterogeneity of particle behavior within the imaging volume. In practice, this 
translates to first measuring the transport rates of individual particles across available 
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frames/time scales, followed by calculating timescale-dependent MSD or Deff at each frame 
based on the particles present in that particular frame, and finally averaging across all frames 
in the movie. This method results in a weighted averaging of particle contributions to MSD 
or Deff calculations, which contrasts sharply with conventional particle tracking analysis that 
inherently assumes particles are present throughout the entire movie and averages across all 
particle traces regardless of the duration they are present in the focal volume.
We applied this ‘frame-by-frame’ approach to both the simulated and experimental data 
described above. Our proposed algorithm indeed recovered the 50-50 distribution of 
‘strongly hindered’ vs. ‘mobile’ particles from simulation (Fig. 3A), with ~50% mobile 
particles at each frame and an average of 49 ± 1% mobile particles across all frames and 
three independent datasets (Fig. S4A and B). In addition to closely matching the expected 
distribution of individual particle Deff, the frame-by-frame ensemble average MSD also 
matched theoretical values well (Fig. 3B; <10% higher at a time scale of 0.2667 s compared 
to 10-fold higher previously). Applying the same approach to the experimental data, the 
average fraction of moving particles decreased from ~84% when analyzed on a trace basis 
to ~49% when analyzed on a frame-by-frame basis, in good agreement with the input 50:50 
beads ratio. Likewise, the ensemble MSD was only ~10% lower than the expected value, 
compared to 5-fold higher previously. For both simulated and experimental data, the small 
differences between theoretical values and measurements produced by the frame-by-frame 
method were statistically insignificant (p > 0.05). Finally, frame-by-frame analysis also 
accurately captured the true particle distribution across the full range of heterogeneity (Fig. 
S5; note for homogeneous populations that frame-by-frame analysis yields almost identical 
results as conventional analysis). This illustrates the broad utility of our approach, which can 
be applied to any particle population.
To illustrate the impact of tracking analysis approach on quantitative evaluation of the 
behavior of drug carrier nanoparticles in biological secretions, we compared first passage 
time estimates (i.e. the time needed for a particle to diffuse across a layer of defined 
thickness) for polymeric nanoparticles (d ~ 100 nm) in human airway mucus, derived from 
conventional vs. frame-by-frame methods (Fig. 4). With the conventional method, the 
estimated time for 10% and 50% of the particles to diffuse across a 50 μm thick mucus 
layer, the approximate thickness of mucus lining the bronchial airways [38], was ~0.8 and 16 
hours, respectively. However, applying the frame-by-frame approach to remove systematic 
bias, the duration required was 1.6 and 46 hours, respectively, implying that a substantially 
lower fraction of the same nanoparticles would be able to penetrate airway mucus, and 
virtually all would be eliminated by mucociliary clearance. For drug delivery applications, 
this suggests a larger particle dose than previously estimated would be needed to achieve the 
desired therapeutic effect. Similar distinct conclusions are reached when we apply the 
analysis to HSV-1 and HIV-1 in human cervicovaginal mucus. Indeed, the time required for 
50% of either HSV-1 or HIV-1 virions to penetrate a ~50 μm thick mucus layer overlaying 
the vaginal epithelium [27] was 30-40 hours by frame-by-frame analysis (i.e., substantially 
longer than the estimated 12-24 hour mucus clearance rate), in sharp contrast to ~1 hour by 
conventional estimate. The marked difference in the fraction of virions estimated to 
penetrate cervicovaginal mucus over time would substantially impact the amount of 
antiretroviral drugs or antibodies that must be dosed to block infection [9, 27]. These results 
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underscore the importance of choosing the correct MPT analytical routine to quantify and 
interpret tracked particle traces.
4. Discussion
Particle tracking is a powerful and popular tool for gaining insight into the transport 
dynamics or fate of drug carrier nanoparticles in biological environments, as well as the 
biochemical or biophysical interactions influencing particle motions. Unfortunately, the 
common practice of quantifying nanoparticle behavior based on simple summation and/or 
averaging of all tracked particle traces can result in misleading biases towards fast-moving 
subpopulations, and consequently far overestimate the extent to which drug carrier 
nanoparticles can overcome specific biological barriers. Here, we show that this bias can be 
easily rectified by the frame-by-frame analytical approach, which can be applied to any set 
of particle tracking data independent of particle speed or tracking algorithm. We believe this 
methodology presents an important step towards objective and accurate assessment of the 
heterogeneous transport behavior of submicron drug carrier particles, which may 
substantially impact conclusions about the efficiencies with which drug carrier nanoparticles 
penetrate biological barriers of interest, as well as conclusions about the microstructural and 
rheological properties of these barriers [11, 39].
The inherent bias in 2D particle tracking towards fast-moving populations at shorter time 
scales may be partially corrected by alternative approaches. For example, we and others [9, 
16, 40] have previously performed tracking analysis only on nanoparticles that remain in the 
focal plane for a minimum of 50 frames, allowing us to obtain more accurate measurement 
of each individual particle trace at a timescale corresponding to 1 s or ~15 frames (n = 35 
data points within 50 frames). This effectively excludes from analysis a large number of 
fast-moving particles present for less than 50 frames in each specimen, which naturally 
reduces the bias towards fast-moving particles (Fig. S5). Nevertheless, this method is 
imperfect because (i) the appropriate minimum number of frames depends on the speed of 
the particles as well as thickness of the focal plane, and (ii) almost all fast-moving outlier 
fractions are omitted from analysis, making it impossible to accurately sample particle 
mobility. Only frame-by-frame analysis, with a low minimum number of frames required, is 
expected to consistently capture the true distribution (Fig. S6). Alternatively, Savin and 
Doyle previously proposed applying a normalized weight proportional to the duration of 
each trajectory to individual particle data before summing to obtain the mean MSD [32], and 
Mellnik et al. presented a method of analyzing trajectories grouped into statistically distinct 
clusters [41]. While these techniques are adept at deriving unbiased ensemble or cluster 
averages, they are not yet widely adopted, and may not readily provide an unbiased 
representation of heterogeneity in particle transport behavior, including the instantaneous 
distribution of particle transport rates. The method described here adds to the prior work by 
capturing the full distribution, including sub-populations of interest, as well as time-
dependent phenomena. In conjunction with techniques such as sub-trajectory analysis [6], 
the frame-by-frame analysis approach may be applied to study, for example, the transport of 
drug carriers delivered with mucolytics that break down mucus over time, or the trapping of 
viruses in mucus by antibodies as they accumulate on the virus surface [27]. Lastly, a 
researcher should in theory obtain the same results as with our frame-by-frame averaging 
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approach by tracking only particles that appear in the very first frame of each video. 
However, this method would require recording and analyzing many more videos to obtain 
the same level of confidence/accuracy.
Although the ‘frame-by-frame’ analytical approach can effectively minimize biases that 
result from inherent heterogeneity in particle motions, a number of limitations to particle 
tracking analysis remain that should be noted when applying MPT in the context of drug 
delivery. First, limited spatiotemporal resolution can result in static and dynamic errors, 
previously discussed by Savin and Doyle [42], particularly for small, inadequately labeled 
and/or fast moving particles. Second, because proportionally fewer fast-moving particles are 
tracked for long durations, the distribution skews toward slower particles at longer time 
scales; this bias cannot be corrected by the frame-by-frame averaging approach as it is a 
fundamental limitation of 2D particle tracking (Fig. 3B and D and Fig. S4C). While rapid 
3D imaging would resolve this problem, the technological requirements continue to be 
prohibitive for most researchers. In particular, accurate 3D particle tracking necessitates a 
high frame rate to follow the motions of rapidly diffusing particles, as well as more complex 
tracking algorithms. As a result, 3D particle tracking remains far less popular than 2D 
particle tracking. Third, MPT analysis is predicated on the ability to accurately capture all 
particles while they are in the focal plane. Although a multitude of tracking algorithms exist, 
the high degree of noise in biological systems, often combined with low signal from 
inadequately labeled nanoparticles or viruses, can make identifying and tracking individual 
nanoparticulates challenging even for the most sophisticated of algorithms. Thus, in most 
instances, it is inadequate to blindly rely on the output of software trackers, and substantial 
human intervention continues to be necessary to ensure accurate tracking and proper 
elimination of imaging artifacts. Fourth, heterogeneity in a system may exist not only within 
each movie but also more globally throughout a sample; in such instances, a larger number 
of videos would be required to capture this level of heterogeneity.
In summary, multiple particle tracking is increasingly used to assess the transport behavior 
of drug and gene carriers in complex biological environments, such as the tumor 
microenvironment or the cell cytoplasm. We introduced here a simple yet rigorous analytical 
routine that avoids a common and significant pitfall with applying conventional multiple 
particle tracking analysis to submicron particles, which frequently results in substantial 
overestimation of particle diffusion kinetics. Our method of weighting particle traces on a 
‘frame-by-frame’ basis is broadly applicable to analysis of all submicron particles 
independent of the particle speed, the nature of the specimen, or trace-linking algorithms, 
and represents an important improvement in the continued use of multiple particle tracking 
to enhance the delivery of therapeutics across major biological barriers.
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Schematic illustrating potential bias in particle tracking of heterogeneous systems. Particles 
that are trapped due to steric or adhesive interactions with the surrounding medium remain 
fixed in place, while those that avoid these interactions diffuse into and out of the focal 
plane. As a result, many more traces may be recorded in the focal plane for fast moving 
(‘Mobile’) particles vs. slow or trapped (‘Strongly hindered’) particles. Black arrows 
indicate moving particles for which two distinct traces were recorded due to the particles 
moving into and out of the focal plane multiple times.
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Application of conventional MPT analysis to simulated and experimental particle trajectory 
data. (A,C) Deff distribution and (B,D) ensemble geometric average MSD based on 
simulated or experimentally measured particle traces, respectively. In (A,C), the vertical 
dashed line indicates the cutoff between strongly hindered and mobile particles (see 
Methods). In (B,D), expected MSD values are based on simulation parameters (B) or the 
geometric average of MSDs for PS-COOH and PS-PEG particles imaged separately (D). 
Error bars represent standard error across 3 independent data sets or mucus samples.
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Application of frame-by-frame analysis to simulated and experimental particle trajectory 
data. (A,C) Deff distribution and (B,D) ensemble geometric average MSD. In (A,C), the 
vertical dashed line indicates the cutoff between strongly hindered and mobile particles (see 
Methods). Error bars represent standard error across 3 independent data sets or mucus 
samples.
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Effect of conventional vs. frame-by-frame analysis on estimates of the time required for (A) 
10% or (B) 50% of particles to pass through a 50 μm thick mucus layer. Data is shown for 
100 nm PS-PEG in human airway mucus, and HSV-1 and HIV-1 in human cervicovaginal 
mucus samples, in which the particles or virions exhibited heterogeneous transport behavior. 
Error bars represent standard error across 3 independent mucus samples. * indicates 
statistically significant difference compared to conventional analysis.
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